|
gptkbp:instanceOf
|
antineoplastic agent
nitrogen mustard
|
|
gptkbp:administeredBy
|
oral tablet
intravenous injection
|
|
gptkbp:approvedBy
|
gptkb:FDA
1959
|
|
gptkbp:ATCCode
|
L01AA01
|
|
gptkbp:brand
|
gptkb:Cytoxan
gptkb:Endoxan
gptkb:Neosar
|
|
gptkbp:CASNumber
|
50-18-0
|
|
gptkbp:chemicalFormula
|
C7H15Cl2N2O2P
|
|
gptkbp:contraindication
|
active infections
severe bone marrow suppression
|
|
gptkbp:discoveredBy
|
gptkb:Arnold_D._Welch
|
|
gptkbp:drugClass
|
antineoplastic agent
immunosuppressant
|
|
gptkbp:eliminationHalfLife
|
3-12 hours
|
|
gptkbp:excretion
|
urine
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
cyclophosphamide
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
DNA crosslinking
inhibits cell division
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
D
|
|
gptkbp:prodrugOf
|
gptkb:acrolein
gptkb:phosphoramide_mustard
|
|
gptkbp:routeOfAdministration
|
oral
intravenous
|
|
gptkbp:sideEffect
|
nausea
vomiting
hair loss
infertility
bone marrow suppression
increased risk of infection
hemorrhagic cystitis
|
|
gptkbp:treatment
|
gptkb:cancer
gptkb:systemic_lupus_erythematosus
leukemia
multiple myeloma
rheumatoid arthritis
nephrotic syndrome
|
|
gptkbp:usedFor
|
gptkb:cancer
immunosuppression
autoimmune diseases
|
|
gptkbp:bfsParent
|
gptkb:granulomatosis_with_polyangiitis
gptkb:CYP3A4
|
|
gptkbp:bfsLayer
|
5
|